Newsmeme!
Discover News you didn't know existed
July 9 (Bloomberg) -- Novartis AG and Fate Therapeutics are racing to develop stem-cell therapies that may save the lives of thousands of blood cancer patients who need a transplant of bone marrow or umbilical-cord blood and can’t find an adequate match.
HAIFA, Israel----Pluristem Therapeutics Inc. , a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient cell therapy products for a variety of disorders, announced today that Griffin Securities has initiated independent research coverage of Pluristem's stock.
PARIS----Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S.
HAIFA, Israel----Pluristem Therapeutics Inc. , a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient cell therapy products for a variety of disorders, announced today that the first patient has been enrolled in a Phase I clinical trial of the Company's allogeneic placental-derived adherent stromal cell product, termed PLX-PAD.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |